Evidence map›Paper›PMID 41228335›Full record

ArticleCancers2025

Artificial Clinic Intelligence (ACI): A Generative AI-Powered Modeling Platform to Optimize Patient Cohort Enrichment and Clinical Trial Optimization.

Choong-Yong Ung, Cristina Correia, Zhuofei Zhang, Carter Caya, Shizhen Zhu, Daniel D Billadeau, Hu Li

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Counterfactual Dermatology With Generative Models.International journal of dermatology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Choong-Yong UngDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Cristina CorreiaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Zhuofei ZhangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Carter CayaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Shizhen ZhuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.ORCID 0000-0002-2929-3279
Daniel D BilladeauDepartment of Immunology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Samar Ibrahim · 2009 to 2026
$22.2M
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)U54AG079779 · NIA · JOHNS HOPKINS UNIVERSITY · PI Darren Baker, JENNIFER H ELISSEEFF · 2022 to 2026
$6.4M
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteinsRF1AG056318 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LI, HU, WOLOZIN, BENJAMIN L · 2018 to 2020
$4.4M
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasisR01CA240323 · NCI · MAYO CLINIC ROCHESTER · PI ZHU, SHIZHEN · 2020 to 2024
$1.8M
Uncovering therapeutic-associated biomarkers via machine learning and feature engineering approachesR03OD034496 · OD · MAYO CLINIC ROCHESTER · PI LI, HU · 2022 to 2022
$318k
NCI NIH HHS P30 CA015083NCI NIH HHS P30CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA240323NIA NIH HHS RF1 AG056318NIA NIH HHS U19 AG074879NIA NIH HHS U54 AG079779NIDDK NIH HHS P30 DK084567NIH HHS P30DK084567NIH HHS P50CA136393NIH HHS R01AG056318NIH HHS R01CA240323NIH HHS R03 OD034496NIH HHS R03OD34496-1NIH HHS U19AG74879NIH HHS U54AG79779
6 · The paper itself

Abstract

Clinical trial enrichment is the targeted recruitment of prospective individual patients with defined clinical characteristics who are likely to benefit from newly developed or repurposed drugs. This process is central to the success of clinical trials together with patient management and regulatory compliance. A main challenge in clinical trial enrichment lies in the recognition of a priori clinical parameters and information that informs drug efficacy or toxicity, particularly when intended for a broader unseen population. Although Artificial Intelligence (AI) approaches, especially large language models (LLMs), have been employed in many aspects of clinical trials, to our knowledge, there is no AI method that has been developed which offers a prospective prediction and assesses the extent to which a given therapeutic intervention benefits an unseen population. Here, we offer an outlook on how to build Artificial Clinic Intelligence (ACI), a generative AI (GAI)-powered modeling platform for modeling clinical trial enrichment. ACI generates synthetic patient data and models clinical trial enrichment to inform clinicians on key clinical parameters that are enriched in prospective patients prior to accrual.

Indexed as

artificial intelligence (AI)clinical trialclinical trial enrichmentdrug testinggenerative AImodelingpatient enrichmentpatient stratification

Identifiers

PMID41228335
PMCPMC12611047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.